(Q33397269)

English

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

scientific article

Statements

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center (English)
Antoine Froissart
Agnès Veyradier
Pascale Poullin
François Provôt
Sandrine Malot
Philippe Vanhille
Jean-Paul Vernant
Dominique Bordessoule
Bertrand Guidet
Eric Mariotte
Eric Rondeau
Karine Clabault
Gabriel Choukroun
Claire Presne
Jacques Pourrat
Mohamed Hamidou
French Thrombotic Microangiopathies Reference Center

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit